Jiangsu Recbio Technology Co., Ltd. (2179)

Overview

Jiangsu Recbio Technology Co., Ltd., positioned within the competitive vaccine industry of the People's Republic of China, specializes in the innovation, development, and commercialization of subunit vaccines. With a foundation date in 2011 and headquartered in Taizhou, Jiangsu Recbio Technology Co., Ltd. dedicates its efforts to confronting some of the world’s most pressing health challenges through its portfolio of vaccine candidates. The company's strategic focus lies in harnessing cutting-edge technologies for the development of vaccines against diseases such as cervical cancer, anal and genital warts, COVID-19, shingles, tuberculosis, influenza, and hand-foot-mouth disease. Through its diversified product pipeline that spans from early pre-clinical stages to advanced phase III clinical trials, Jiangsu Recbio is making significant strides towards contributing to global health security and advancing public health outcomes.

Products and Services

• REC603: A recombinant human papillomavirus (HPV) 9-valent vaccine, currently in phase III clinical trial, aimed at addressing cervical cancer, and anal and genital warts.
• REC601 and REC602: Both are recombinant HPV bivalent vaccines, in phase I clinical trials, targeting prevention against HPV-related conditions.
• REC604a: A recombinant HPV quadrivalent vaccine, in the pre-clinical stage, designed to expand protection against additional strains of HPV.
• REC604b: Another recombinant HPV 9-valent vaccine in pre-clinical stage, aligning with the company's focus on broadening HPV vaccine coverage.
• ReCOV: A recombinant COVID-19 vaccine candidate currently being tested in Phase II/III clinical trial, which marks the company's timely response to the global pandemic.
• R520A: This pre-clinical stage messenger ribonucleic acid (mRNA) COVID-19 vaccine candidate represents Jiangsu Recbio’s investment in the cutting-edge mRNA technology for vaccine development.
• REC610: A recombinant shingles vaccine now in Phase I clinical trial, aiming to provide immunity against shingles, a painful condition caused by the varicella-zoster virus.
• REC607: Operating in the pre-clinical phase, this virus vectored adult tuberculosis vaccine contributes to the global fight against tuberculosis.
• REC606: Another novel approach to combating adult tuberculosis, this recombinant vaccine is also in the pre-clinical stage.
• REC617: A recombinant influenza quadrivalent vaccine in pre-clinical stage, developing broader protection against seasonal influenza viruses.
• REC605: Focused on childhood diseases, this recombinant hand-foot-mouth disease quadrivalent vaccine is in the pre-clinical phase, aiming to safeguard against this common viral illness among children.